Media and Communications

News

Finance

Thursday, May 02, 2013
Teva Reports First Quarter 2013 Results

Click here for Webcast Net Revenues Total $4.9 Billion Non-GAAP Diluted EPS of $1.12; GAAP Diluted EPS of $0.74 Cash Flow from Operations of $1.1 Billion JERUSALEM--(BUSINESS WIRE)--May. 2, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended March 31, 2013. “During the quarter, we were pleased by the overall performance of our specialty products and results of our OTC joint venture. Our generic operations, which are a core component of our business, performed in line with our expectations and were particularly strong in Western and East Read More »

Friday, March 08, 2013
Teva Files 2012 Annual Report on Form 20-F

JERUSALEM--(BUSINESS WIRE)--Mar. 8, 2013-- In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has filed its 2012 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company’s website at www.tevapharm.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company’s complete aud Read More »

Friday, March 01, 2013
Teva Calls 5.550% Senior Notes Due 2016 for Redemption

JERUSALEM--(BUSINESS WIRE)--Mar. 1, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that its finance subsidiary Teva Pharmaceutical Finance Company, LLC has called for redemption its approximately $500 million outstanding principal amount of 5.550% Senior Notes due 2016 (CUSIP No. 88163V AC3). The redemption is being funded with cash on hand. The redemption date will be March 22, 2013, and the redemption price will equal the principal amount of the notes plus a make whole premium calculated in accordanc Read More »

Thursday, February 07, 2013
Teva Reports Fourth Quarter and Full Year 2012 Results

Fourth Quarter 2012 Net Revenues of $5.2 Billion and Full Year Net Revenues of $20.3 Billion Fourth Quarter 2012 Non-GAAP Diluted EPS of $1.32, GAAP Diluted EPS of $0.37; Full Year Non-GAAP Diluted EPS of $5.35, GAAP Diluted EPS of $2.25 15% Increase in Quarterly Dividend Share Repurchases of $0.5 Billion and $1.2 Billion in Fourth Quarter and Full Year 2012, Respectively Cash Flow from Operations of $1.6 Billion and $4.6 Billion in Fourth Read More »

Tuesday, January 22, 2013
Teva to Report Fourth Quarter and Full Year 2012 Financial Results on February 7, 2013

JERUSALEM--(BUSINESS WIRE)--Jan. 22, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its fourth quarter and full year 2012 financial results on Thursday, February 7, 2013 at 7:00 a.m. EST. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. EST to discuss its fourth quarter and full year 2012 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the following num Read More »

Tuesday, December 18, 2012
Teva Calls 1.700% Senior Notes Due 2014 for Redemption

- Closes $2 Billion Senior Note Offering - JERUSALEM--(BUSINESS WIRE)--Dec. 18, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that its finance subsidiary Teva Pharmaceutical Finance IV, LLC has called for redemption its $1 billion outstanding principal amount of 1.700% senior notes due 2014 (CUSIP No. 88166H AA5). The redemption is being funded with proceeds from Teva’s offering of $2 billion principal amount of senior notes, which priced on December 13, 2012 and closed earlier today. T Read More »

Tuesday, December 18, 2012
Teva Signs New $3.0 Billion Syndicated Revolving Credit Facility

New Facility to Replace Existing $2.5 Billion Facility Secures Teva's Liquidity through Revolving Credit Lines JERUSALEM--(BUSINESS WIRE)--Dec. 18, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has entered into a new five-year, $3.0 billion unsecured revolving credit facility, which replaces its existing $2.5 billion credit facility. “By signing this new revolving credit facility, with its increased size and extended term, we took another step on our recently announced new Read More »

Thursday, December 13, 2012
Teva Receives A- Rating from Fitch Ratings with a Stable Outlook

JERUSALEM--(BUSINESS WIRE)--Dec. 13, 2012-- Teva Pharmaceutical Industries Limited (NYSE: TEVA) announced today that Fitch Ratings have assigned to it an initial long term issuer rating of A-, with a stable outlook. The credit rating agency said that the rating reflects Teva’s strategic position as the world's largest generic drug manufacturer, financial discipline, strong cash flow and liquidity, and capital deployment toward debt reduction. “Our decision to obtain a credit rating from Fitch further supports our Read More »

Thursday, December 13, 2012
Teva Announces Pricing of $2.0 Billion of Senior Notes

- Proceeds to be used for repayment of existing debt - JERUSALEM--(BUSINESS WIRE)--Dec. 13, 2012-- Teva Pharmaceutical Industries Limited (NYSE: TEVA) announced today that it successfully priced a debt offering by its special purpose finance subsidiaries, consisting of two tranches: $700,000,000 of 2.250% fixed rate senior notes maturing in March 2020 issued by Teva Pharmaceutical Finance IV, LLC; and $1,300,000,000 of 2.950% fixed rate senior notes maturing in December 2022 issued by Teva Pharmaceutical Finance Company BV The notes will be sold at a price of $999.55 and $998.02 per Read More »

Friday, November 30, 2012
Teva Provides 2013 Non-GAAP Financial Outlook

2013 Non-GAAP Diluted EPS of $4.85 to $5.15 JERUSALEM--(BUSINESS WIRE)--Nov. 30, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) provided its current outlook for non-GAAP financial performance for the full year ending December 31, 2013. Financial Targets: Total net revenues of between $19.5-$20.5 billion, consisting of:   Region   Net Revenues United States   $10.0 to $10.6B Europe   $5.5 to $6.1B Rest of World   $3.7 to $4.3B Total net revenues include the following major business lines: Generic medicines (including API) net reve Read More »

​​​